TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...
During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...
Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over ...
TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...
During the last three months, 4 analysts shared their evaluations of TG Therapeutics (NASDAQ:TGTX), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ...
Investor's Business Daily on MSN3d
IBD 50's TG Therapeutics Rises On Five-Year Data For Multiple Sclerosis DrugTG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...
TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.19 which represents a slight increase of $0.12 or 0.52% from the prior close of $23.07. The stock opened at $22 ...
As of the latest trading close, TGTX, a Healthcare sector stock, is trading -3.15% below its 52-week high but remains 285.29% above its 52-week low. The Average True Range (ATR) (14 days) of 1.42 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback